G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:33:21 2024-04-26 am EDT			5-day change	1st Jan Change
3.95 ^USD	+2.33%		-4.01%	+29.34%

Feb. 28	G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 28	Wedbush Lifts G1 Therapeutics' PT to $5 From $4, Adjusts Financing, Revenue Expectations; Keeps Outperform Rating	MT

G1 Therapeutics, Inc. Announces Resignation of Seth A. Rudnick from Board of Directors

October 15, 2021 at 04:06 pm EDT

G1 Therapeutics, Inc. announced that Seth A. Rudnick, M.D., notified the company of his decision to resign from the Board of Directors of the company effective immediately as of October 13, 2021. Dr. Rudnick was a member of the Board since 2014.

Latest news about G1 Therapeutics, Inc.

G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Wedbush Lifts G1 Therapeutics' PT to $5 From $4, Adjusts Financing, Revenue Expectations; Keeps Outperform Rating	Feb. 28	MT
Transcript : G1 Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q4 Revenue $14.9M	Feb. 28	MT
G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024	Feb. 28	CI
G1 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Top Midday Decliners	Feb. 13	MT
Caution Ahead of Key Inflation Data Weighs on Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	Feb. 13	MT
Needham Adjusts G1 Therapeutics Price Target to $12 From $14, Maintains Buy Rating	Feb. 13	MT
G1 Therapeutics Gets Nod for Continuing Breast Cancer Study But CEO Notes Lack of 'Positive Interim Analysis'; Shares Drop Premarket	Feb. 13	MT
Wedbush Adjusts G1 Therapeutics' PT to $4 From $5, Keeps Outperform Rating	Feb. 13	MT
G1 Therapeutics Gets Continuation Recommendation From Data Monitoring Committee for Phase 3 Breast Cancer Study	Feb. 13	MT
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee	Feb. 12	CI
Transcript : G1 Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM	Jan. 10
G1 Therapeutics, Inc. Announces Updates, Including Encouraging Preliminary Overall Survival Data from the Ongoing Phase 2 Trial of Trilaciclib in Combination with the ADC Sacituzumab Govitecan in Patients with TNBC	Jan. 08	CI
Simcere Pharma Gets Authorization to Produce Imported Cancer Drug in Hainan Facility	Dec. 28	MT
G1 Therapeutics, Inc.(NasdaqGS:GTHX) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
G1 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
Transcript : G1 Therapeutics, Inc., Q3 2023 Earnings Call, Nov 01, 2023	Nov. 01
Earnings Flash (GTHX) G1 THERAPEUTICS Posts Q3 Revenue $12.3M, vs. Street Est of $14.2M	Nov. 01	MT
G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023	Nov. 01	CI
G1 Therapeutics' COSELA(R) (Trilaciclib) Recommends in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology	23-10-18	CI
North American Morning Briefing : Stock Futures -2-	23-10-09	DJ
JPMorgan Downgrades G1 Therapeutics to Underweight From Neutral	23-10-06	MT
G1 Therapeutics, Inc. Announces Resignation of Mark A. Velleca from the Board of Directors, Effective as of September 30, 2023	23-09-21	CI

Chart G1 Therapeutics, Inc.

Duration

Period

More charts

Company Profile

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for G1 Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.86 USD

Average target price

8.5 USD

Spread / Average Target

+120.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
G1 THERAPEUTICS, INC.	+29.34%	201M
VERTEX PHARMACEUTICALS INCORPORATED	-2.28%	103B
REGENERON PHARMACEUTICALS, INC.	+0.47%	95.71B
ARGENX SE	+1.80%	22.02B
BIONTECH SE	-16.71%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-15.07%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.73%	13.86B
SAREPTA THERAPEUTICS, INC.	+34.05%	12.04B

Bio Therapeutic Drugs